Please go to the PowerPak homepage
and select a course.
Acquired Hemophilia A: What the Hospital Pharmacist Needs to Know
Jointly provided by Postgraduate Institute for Medicine and CMEology.
This activity is supported by an independent educational grant from Baxalta US Inc.
This activity will be designed to meet the needs of hospital pharmacists and other healthcare providers involved in the care of patients with bleeding disorders.
On completion of this activity, participants should be able to:
- Recognize AHA in patients with atypical bleeding patterns
- Discuss the diagnosis and prognosis of AHA
- Assess strategies for the hemostatic treatment of AHA
- Describe approaches to inhibitor eradication in AHA
- Provide accurate and appropriate counsel as part of the treatment team
William E. Dager, PharmD, BCPS, MCCM, FCSHP, FCCM, FCCP, FASHP (Chairperson)
University of California, Davis Medical Center
Clinical Professor of Medicine
UC Davis School of Medicine
Clinical Professor of Pharmacy
UC San Francisco School of Pharmacy and
Touro University California College of Pharmacy
San Francisco, California
Miguel A. Escobar, MD
Professor of Medicine and Pediatrics
Department of Hematology
University of Texas Health Science Center
and MD Anderson Cancer Center
Gulf States Hemophilia and Thrombophilia Center
R. Donald Harvey, PharmD, FCCP, BCOP
Associate Professor, Hematology/Medical Oncology
Director, Phase I Program, Winship Cancer Institute
Emory University School of Medicine
Accreditation Statement: Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credit Designation: Postgraduate Institute for Medicine designates this continuing education activity for 1.5 hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number 0809-9999-16-246-H01-P). If you received credit for 0809-9999-15-293-L01-P, you are not eligible to receive credit for this activity.
Type of Activity: Knowledge
How to Obtain Credit
During the period March 25, 2016 through March 25, 2017, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and the evaluation form. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on Grade Exam at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 75% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 75%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
|Name of Faculty or Presenter
||Reported Financial Relationship
|William E. Dager, PharmD, BCPS, MCCM, FCSHP,
FCCM, FCCP, FASHP
|No financial relationships to report
|Miguel A. Escobar, MD
||Consulting Fees: Baxalta, Bayer, Kedrion Biopharma, LFB, Novo Nordisk, Pfizer Inc
Research support: Pfizer Inc, National Hemophilia Foundation
Participate in Clinical Trials Supported by: Baxalta US Inc., Bayer, Biogen Idec, CSL Behring, Novo Nordisk, Octapharma AG, OPKO Biologics Ltd, Pfizer Inc.
|R. Donald Harvey, PharmD, FCCP, BCOP
||Consulting Fees (spouse): Baxalta US Inc., Biogen
Contracted Research (spouse): Baxalta US Inc., Novo Nordisk
The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following CMEology planners and managers, Sylvie Laflamme, Rob Lowney, and Truc Diep, PhD, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Method of Participation and Request for Credit
There are no fees for participating and receiving CE credit for this activity. During the period March 25, 2016 through March 25, 2017, participants must read the learning objectives and faculty disclosures and study the educational activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.